Tailored in vivo half-life

Hoefman S, Ottevaere I, Baumeister J, Sargentini-Maier M-L. Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies. Antibodies 2015, 4, 141-156.

Vosjan MJWD, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GAMS. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 2012;11:1017-1025.

Coppieters K, Dreier T, Silence K, Haard HD, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Wiele CV, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P.  Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.  Arthritis Rheum. 2006 Jun; 54 (6): 1856-66.

Harmsen MM, Van Solt CB, Fijten HP, Van Setten MC.  Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins.  Vaccine. 2005 Sep 30; 23 (41): 4926-34.

Gibbs WW.  Nanobodies.  Sci Am. 2005 Aug; 293 (2): 78-83.

Muyldermans S.  Single domain camel antibodies: current status.  J Biotechnol. 2001 Jun; 74 (4): 277-302.

< back